Engineered Histidine‐Rich Peptides Enhance Endosomal Escape for Antibody‐Targeted Intracellular Delivery of Functional Proteins
Angewandte Chemie International Edition · 2023
DOI: 10.1002/anie.202304692 ↗Kurz gefasst
Fachartikel in der Zeitschrift Angewandte Chemie International Edition, 2023. Verfasst von Yan Zhao und 4 weiteren Autor:innen. Beteiligte Einrichtung: School of Pharmaceutical Sciences, MOE Key Laboratory of Bioorganic Phosphorus Chemistry & Chemical Biology, Tsinghua University, Beijing, 100084, Ch…. Hauptthemen laut MEDLINE: Histidine, Cell-Penetrating Peptides. Die Arbeit wurde bisher 37-mal zitiert (Crossref) und nennt 48 Literaturangaben. Gefördert von: Tsinghua Initiative Scientific Research Program, Key Technologies Research and Development Program, Center for Life Sciences.
Abstract (Originalsprache)
Currently, the clinical application of protein/peptide therapeutics is mainly limited to the modulation of diseases in extracellular spaces. Intracellular targets are hardly accessed, owing largely to the endosomal entrapment of internalized proteins/peptides. Here, we report a strategy to design and construct peptides that enable endosome‐to‐cytosol delivery based on an extension of the “histidine switch” principle. By substituting the Arg/Lys residues in cationic cell‐penetrating peptides (CPPs) with histidine, we obtained peptides with pH‐dependent membrane‐perturbation activity. These peptides do not randomly penetrate cells like CPPs, but imitate the endosomal escape of CPPs following cellular uptake. Working with one such 16‐residue peptide (hsLMWP) with high endosomal escape capacity, we engineered modular fusion proteins and achieved antibody‐targeted delivery of diverse protein cargoes—including the pro‐apoptotic protein BID (BH3‐interacting domain death agonist) and Cre recombinase—into the cytosol of multiple cancer cell types. After extensive in vitro testing, an in vivo analysis with xenograft mice ultimately demonstrated that a trastuzumab‐hsLMWP‐BID fusion conferred strong anti‐tumor efficacy without apparent side effects. Notably, our fusion protein features a modular design, allowing flexible applications for any antibody/cargo combination of choice. Therefore, the potential applications extend throughout life science and biomedicine, including gene editing, cancer treatment, and immunotherapy.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- School of Pharmaceutical Sciences, MOE Key Laboratory of Bioorganic Phosphorus Chemistry & Chemical Biology, Tsinghua University, Beijing, 100084, China.
- Peking University-Tsinghua University-National Institute Biological Sciences (PTN) Joint Graduate Program, School of Life Sciences, Tsinghua University, Beijing, 100084, China.
- Academy for Advanced Interdisciplinary Studies (AAIS), Peking University-Tsinghua University-National Institute Biological Sciences (PTN) Joint Graduate Program, Peking University, Beijing, 100871, China.
ORCID-Profile: Juanjuan Du
Förderung
- Tsinghua Initiative Scientific Research Program
- Key Technologies Research and Development Program
- Center for Life Sciences
Zitieren
APA
Zhao, Y., Jiang, H., Yu, J., Wang, L., & Du, J. (2023). Engineered Histidine‐Rich Peptides Enhance Endosomal Escape for Antibody‐Targeted Intracellular Delivery of Functional Proteins. Angewandte Chemie International Edition. https://doi.org/10.1002/anie.202304692
Vancouver
Zhao Y, Jiang H, Yu J, Wang L, Du J. Engineered Histidine‐Rich Peptides Enhance Endosomal Escape for Antibody‐Targeted Intracellular Delivery of Functional Proteins. Angewandte Chemie International Edition. 2023. doi:10.1002/anie.202304692
BibTeX
@article{Zhao2023,
author = {Zhao, Yan and Jiang, Haolin and Yu, Jiazhen and Wang, Luyao and Du, Juanjuan},
title = {Engineered Histidine‐Rich Peptides Enhance Endosomal Escape for Antibody‐Targeted Intracellular Delivery of Functional Proteins},
journal = {Angewandte Chemie International Edition},
year = {2023},
doi = {10.1002/anie.202304692}
}
EUVIMED